The radiopropharmaceutical 18F-NaF (sodium fluoride) is produced at the Nuclear Medicine Center of the Medical Center Hospital of the President’s Affairs Administration of the Republic of Kazakhstan. Currently, PET/CT studies using this drug were conducted in the first patients and showed successful results. Therefore, the main purpose of the radiopharmaceutical is to detect both primary and metastatic neoplasms of bone tissue.
Keep in mind that the 18F-NaF PET/CT examination is performed only by the prescription of an oncologist. Physicians choose a diagnostic algorithm based on patient complaints and the results of clinical and laboratory studies.
According to Aigul Saduakasova, Head of the Nuclear Medicine Department MD of the Medical Center Hospital of the President’s Affairs Administration of the Republic of Kazakhstan, the center is fully prepared to accept patients with such diagnoses.
Worth noting that the unique Nuclear Medicine Center, located in the capital, began its work in October 2022. The center's specialists conducted more than 6,000 studies last year. And the first radiopharmaceutical was produced and put into operation in December 2022. According to the specialists, the third radiopharmaceutical is planned for June of this year.
